KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Emergent BioSolutions (EBS) EBITDA (2016 - 2025)

Historic EBITDA for Emergent BioSolutions (EBS) over the last 17 years, with Q3 2025 value amounting to $76.5 million.

  • Emergent BioSolutions' EBITDA rose 1860.47% to $76.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $118.5 million, marking a year-over-year increase of 18286.71%. This contributed to the annual value of -$108.7 million for FY2024, which is 8503.58% up from last year.
  • Emergent BioSolutions' EBITDA amounted to $76.5 million in Q3 2025, which was up 1860.47% from $1.6 million recorded in Q2 2025.
  • Over the past 5 years, Emergent BioSolutions' EBITDA peaked at $286.8 million during Q4 2021, and registered a low of -$292.9 million during Q2 2023.
  • For the 5-year period, Emergent BioSolutions' EBITDA averaged around -$28.2 million, with its median value being -$9.5 million (2024).
  • Per our database at Business Quant, Emergent BioSolutions' EBITDA surged by 89482.76% in 2021 and then tumbled by 223913.04% in 2023.
  • Quarter analysis of 5 years shows Emergent BioSolutions' EBITDA stood at $286.8 million in 2021, then tumbled by 119.28% to -$55.3 million in 2022, then rose by 20.8% to -$43.8 million in 2023, then soared by 78.31% to -$9.5 million in 2024, then skyrocketed by 905.26% to $76.5 million in 2025.
  • Its EBITDA stands at $76.5 million for Q3 2025, versus $1.6 million for Q2 2025 and $49.9 million for Q1 2025.